初诊多发性骨髓瘤患者微小残留病状态动态监测的预后意义
纳入105例治疗后达VGPR及以上的初诊MM患者,用多参数流式细胞术动态监测MRD。MRD转阴率72.4%(76/105),中位转阴时间3个月;持续MRD阳性为PFS独立不良因素(HR=3.039)。失去MRD阴性状态预后劣于持续阴性,MRD阴性持续时间与复发/死亡风险降低相关。
要点
- MRD阴性患者2年PFS率62.2%高于MRD阳性41.3%(P=0.001)
- 持续MRD阳性为PFS独立不良因素(HR=3.039,95%CI 1.029-8.974)
- MRD阴性持续时间≥12个月者2年PFS 77.7% vs 36.7%(P<0.001)
核心结论
- 持续MRD阳性是MM独立的预后不良因素,MRD阴性持续时间也是重要预后因素。
- 失去MRD阴性状态可能是复发的早期标志,动态监测MRD有助于指导复发MM治疗时机的选择。
研究设计与样本
- 筛选135例初诊MM患者,纳入其中治疗后最佳疗效达VGPR及以上的105例。
- 采用多参数流式细胞术(MFC)在治疗2个周期后多个时间点监测MRD直至临床复发、死亡或末次随访。
- 统计方法包括Kaplan-Meier分析和Cox回归等。
主要发现
- 全部135例中57.8%(78/135)治疗后达MRD阴性;纳入的105例中MRD转阴率72.4%(76/105),中位转阴时间3个月。
- MRD阴性患者2年PFS率62.2% vs MRD阳性41.3%(P=0.001),持续MRD阳性为PFS独立不良因素(多因素分析P=0.044,HR=3.039,95%CI 1.029-8.974)。
- 失去MRD阴性(转阳)者中位PFS 18个月 vs MRD持续阴性者未达到(P<0.001),中位OS两者均未达到(P=0.002)。
- MRD阴性持续时间≥12个月者2年PFS 77.7% vs 对照组36.7%(P<0.001),2年OS 96.4% vs 57.9%(P<0.001)。
- MRD阴性持续时间与复发/死亡风险降低相关(PFS单因素:P<0.001,HR=0.865,95%CI 0.815-0.918;OS单因素:P=0.001,HR=0.850,95%CI 0.741-0.915)。
关键数值与推荐
- 高危细胞遗传学异常(CA)患者中,MRD阴性者中位PFS未达到 vs 19个月(P=0.006)。
- 不适合ASCT患者中,MRD阴性者中位PFS未达到 vs 25个月(P=0.052)。
- 硼替佐米方案治疗者中位MRD阴性持续时间25个月 vs 10个月(P=0.034)。
临床怎么用
- 作者认为动态监测MRD有助于指导复发MM治疗时机的选择。
- 作者认为失去MRD阴性状态可能作为复发的早期标志。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the prognostic value of kinetic changes in minimal residual disease (MRD) status, as well as its relationship with risk stratification, therapeutic response and treatment in patients with newly-diagnosed multiple myeloma (MM) . Methods: A total of 135 patients with newly-diagnosed MM were screened, and 105 patients who achieved VGPR or more as the best responses were included into this study. The MRD status was determined by multiparameter flow cytometry (MFC) at multiple intervals after two cycles of treatment until clinical relapse, death, or last follow-up. The statistical methods included Kaplan-Meier analysis, Cox regression, etc. Results: ①In all 135 patients, 57.8% (78/135) patients achieved MRD negativity (MRD(-)) after treatment. In 105 patients who achieved VGPR and thus included in this study, the MRD(-) rate was 72.4% (76/105) , with a median interval of 3 months from starting treatment to achievement of MRD(-) status. ②The 2-year PFS rate of patients with MRD(-) status was significantly higher than that of MRD(+) status (62.2% vs 41.3%, P=0.001) , while MRD persistence (MRD(+)) was an independent factor for poor prognosis (multivariate analysis for PFS: P=0.044, HR=3.039, 95%CI 1.029-8.974) . ③Loss of MRD(-) status (i.e., MRD reappearance) showed inferior outcomes compared with MRD sustained negative ones, the PFS was 18 months versus not reach (P<0.001) and the OS was not reach for both (P=0.002) . ④The 2-year PFS and OS rates of patients with duration of MRD(-)status≥12 months were significantly higher than those of the control group (PFS: 77.7% vs 36.7%, P<0.001; OS: 96.4% vs 57.9%, P<0.001 respectively) . Duration of MRD(-) status was associated with a marked reduction in risk of relapse or death (univariate analysis for PFS: P<0.001, HR=0.865, 95%CI 0.815-0.918; for OS: P=0.001, HR=0.850, 95%CI 0.741-0.915 respectively) . ⑤Moreover, even in patients carrying high-risk cytogenetic abnormalities (CA) or ineligible for ASCT, MRD negativity remained its prognostic value to predict PFS (high-risk CA medianPFS: not reach vs 19 months, P=0.006; ineligible for ASCT medianPFS: not reach vs 25 months, P=0.052 respectively) . ⑥Last, treatment with the bortezomib-based regimens contributed to prolonged MRD(-) duration (median MRD(-) duratio: 25 months vs 10 months, P=0.034) . Conclusion: Our findings supported MRD(+) status as an independent poor prognostic factor in MM patients, which implicated that duration of MRD(-) status also played a significant role in evaluation of prognosis, while loss of MRD(-)status might serve as an early biomarker for relapse. Therefore, monitoring of MRD kinetics might more precisely predict prognosis, as well as guide treatment decision, especially for when to start retreatment in relapsed patients. 目的: 探讨多发性骨髓瘤(MM)患者微小残留病(MRD)动态变化及其与临床特征、治疗和预后的关系。 方法: 纳入105例治疗后达到非常好的部分缓解(VGPR)的MM患者,采用多参数流式细胞术(MFC)动态监测MRD状态,结合临床数据和随访,进行Kaplan-Meier曲线及Cox回归等分析。 结果: ①纳入本研究的疗效VGPR患者中,MRD转阴率为72.4%(76/105),中位转阴时间为3个月。②MRD阴性患者2年无进展生存(PFS)率明显高于MRD阳性患者(62.2%对41.3%,P=0.001),持续MRD阳性为PFS独立预后不良因素(HR=3.039,P=0.044)。③失去MRD阴性状态(转阳)患者预后劣于MRD持续阴性患者,二者中位PFS时间分别为18个月和未达到(P<0.001),中位总生存(OS)时间均未达到(P=0.002)。④MRD阴性持续时间≥12个月患者的2年PFS和OS率均显著高于对照组(PFS:77.7%对36.7%,P<0.001;OS:96.4%对57.9%,P<0.001)。随MRD阴性持续时间延长,复发/死亡风险显著降低(PFS:HR=0.865,P<0.001;OS:HR=0.823,P<0.001)。⑤高危细胞遗传学异常(CA)或不适合自体造血干细胞移植(ASCT)患者中,MRD阴性患者PFS延长(高危CA患者中位PFS:未达到对19个月,P=0.006;不适合ASCT患者中位PFS:未达到对25个月,P=0.052)。⑥应用硼替佐米治疗可明显延长MRD阴性持续时间(中位MRD阴性持续时间:25个月对10个月,P=0.034)。 结论: 持续MRD阳性是MM独立的预后不良因素,MRD阴性持续时间是另一重要预后因素,而失去MRD阴性状态可能是复发的早期标志,故动态监测MRD有助于指导复发MM治疗时机的选择。.
引用
- Yang PY, Liu MM, Fan HQ, et al. [The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 32397022. doi:10.3760/cma.j.issn.0253-2727.2019.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。